New drug combo shows promise for Hard-to-Treat ovarian cancer
NCT ID NCT05494580
First seen Apr 04, 2026 · Last updated May 15, 2026 · Updated 9 times
Summary
This study tested a combination of two drugs, pamiparib and surufatinib, in 29 women with a tough-to-treat type of ovarian cancer that had stopped responding to platinum chemotherapy and a prior PARP inhibitor. The goal was to see if the combo could shrink tumors or slow cancer growth. The approach targets cancer cells and the blood vessels that feed tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Cetntre
Guangzhou, 510060, China
Conditions
Explore the condition pages connected to this study.